TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07620561: Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients

Sponsor: University of Maryland, Baltimore · Phase: PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 20 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$1,625,400

Rescue Site Savings

+$1,083,600

Unlock Full NCT07620561 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07620561 Rescue Dossier →